## At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

- 1
- Nagendrakumar Balasubramanian Singanallur $^{1\dagger}$ , Petrus Jansen van Vuren $^{1\dagger}$ , Alexander J McAuley $^{1\dagger}$ , Matthew P Bruce $^{1}$ , Michael J Kuiper $^{2}$ , StellaMay Gwini $^{3,4}$ , Shane Riddell $^{1}$ , Sarah 2
- Goldie<sup>1</sup>, Trevor W Drew<sup>1</sup>, Kim R Blasdell<sup>1</sup>, Mary Tachedjian<sup>1</sup>, Shruthi Mangalaganesh<sup>1,5</sup>, 3
- Simran Chahal<sup>1</sup>, Leon Caly <sup>6</sup>, Julian D Druce<sup>6</sup>, Jennifer A Juno<sup>7</sup>, Stephen J Kent<sup>7</sup>, Adam K 4
- Wheatley<sup>7</sup>. Seshadri Vasan<sup>1,8</sup>\* 5
- 6 <sup>1</sup>Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial
- 7 Research Organisation (CSIRO) Health and Biosecurity, Geelong, VIC 3220, Australia
- 8 <sup>2</sup>Data61, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Docklands 3008,
- 9 VIC. Australia
- <sup>3</sup>Biostatistics Support Service, Barwon Health, Geelong, VIC 3220, Australia 10
- <sup>4</sup>School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, 11
- 12 Australia
- <sup>5</sup>Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia 13
- 14 <sup>6</sup>Victorian Infectious Diseases Reference Laboratory (VIDRL), The Peter Doherty Institute for
- Infection and Immunity, Melbourne, VIC 3000, Australia 15
- 16 <sup>7</sup>Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty
- Institute for Infection and Immunity, Melbourne, VIC 3000, Australia 17
- <sup>8</sup>Department of Health Sciences, University of York, York, YO10 5DD, United Kingdom 18
- 19 <sup>†</sup>These authors have contributed equally to this work and share first authorship
- 20 \*Correspondence:
- 21 Prof. Seshadri S. Vasan, vasan.vasan@csiro.au; orcid.org/0000-0002-7326-3210

### **Abstract**

- 23 Plasma samples taken at different time points from donors who received either AstraZeneca
- 24 (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19)
- 25 vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern
- 26 and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50%
- 27 neutralizing antibody titres (NT<sub>50</sub>) against Delta and VIC31 at 6 months compared to 2 weeks after
- 28 the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of
- 29 Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres
- 30 below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks
- 31 after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold
- 32 lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender
- 33 were not found to significantly impact our results. These observations indicate that vaccine matching
- 34 may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient
- 35 neutralising antibodies against emerging variants of concern, especially Omicron, amidst the
- 36 challenges of ensuring vaccine equity worldwide.
- Keywords: AlphaFold; BA.1.1; biomolecular modelling; COVID-19; neutralising antibody 37
- 38 titres; SARS-CoV-2; Spike protein; variants of concern; vaccines; vaccine matching

## Introduction

The novel coronavirus disease-19 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in circa 420 million cases and 6 million deaths, and is yet to be brought under control [1]. Only 14.2 vaccine doses have been administered per 100 people in 'low-income countries'; for 'lower middle income countries' excluding India the number is 81.6 doses per 100 people [2]. Thus, half the world's population is still receiving the first dose of a COVID-19 vaccine and is very vulnerable. Although vaccines can reduce the likelihood of infection, re-infection and disease severity in individuals, and to an extent community transmission, the continuous emergence of SARS-CoV-2 variants of concern (VOC) has frustrated global response efforts and highlighted the importance of continued assessment of vaccine efficacy. The World Health Organization has declared 5 VOC to date, viz. Alpha (18 December 2020), Beta (18 December 2020), Gamma (11 January 2021), Delta (11 May 2021), Omicron (26 November 2021), of which Delta and Omicron are currently of the greatest concern and two variants of interest (VOI) viz. Lambda (14 June 2021) and Mu (30 August 2021) [3].

While studies on T-cell responses will provide a more holistic picture of vaccine-induced efficacy, assessment of neutralising antibody reactivity against emerging VOC, such as Omicron (B.1.1.529, referred to as BA.1 henceforth), can help inform near-term public health response. This is especially important for the vaccines manufactured by Pfizer, Moderna, and AstraZeneca, as one or more of these three are approved in 192 countries (which does not include the People's Republic of China), representing 77% of the world's population [2]. In this study we have assessed the ability of human plasma samples collected from vaccinated donors at different timepoints to neutralise the current two most globally-prevalent VOC (Delta and Omicron) in comparison with a reference isolate used in previous studies (VIC31; [4]). We have also bolstered our interpretation using *in silico* modelling of the respective Spike proteins, and outlined our thoughts on future follow-up studies.

### **Materials and Methods**

### SARS-CoV-2 Stock Generation and Characterisation

Three SARS-CoV-2 isolates, VIC31 (hCoV-19/Australia/VIC31/2020 containing D614G mutation), Delta variant of concern (hCoV-19/Australia/VIC18440/2021), and Omicron BA.1.1 variant of concern (hCoV-19/Australia/VIC28585/2021) were provided by the Victorian Infectious Diseases Reference Laboratory (VIDRL; Melbourne, Australia). Virus stocks were propagated and titrated in Vero E6 cells (American Type Culture Collection (ATCC), Manassas, VA, USA) prior to use as previously outlined in [5]. Briefly, VeroE6 cells were grown in 150 cm² flasks in Dulbecco's Modified Eagle Medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS), 2mM GlutaMAX supplement, 100U/mL penicillin, and 100 μg/mL streptomycin (all components from ThermoFisher Scientific; Scoresby, VIC, Australia) until >80% confluent. Virus isolates were diluted 1:100 in DMEM (containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and 100 μg/mL streptomycin), and 5 mL was used to inoculate Vero E6 cells for 1 hr at 37°C/5% CO<sub>2</sub> before additional media was added to the flask. The flasks were incubated at 37°C/5% CO<sub>2</sub> for 48 h (for VIC31 and Delta) or 72 hr (for Omicron) before supernatant was clarified at 2,000 x g for 10 min, and harvested and stored in 1 mL aliquots at -80 °C.

Identity of virus stocks were confirmed by next-generation sequencing using a MiniSeq platform (Illumina, Inc; San Diego, CA, USA). In brief,  $100 \,\mu\text{L}$  cell culture supernatant from infected Vero E6 cells was combined with  $300 \,\mu\text{L}$  TRIzol reagent (Thermo Fisher Scientific) and

- 82 RNA was purified using a Direct-zol RNA Miniprep kit (Zymo Research; Irvine, CA, USA). Purified
- 83 RNA was further concentrated using an RNA Clean-and-Concentrator kit (Zymo Research), followed
- by quantification on a DeNovix DS-11 FX Fluorometer. RNA was converted to double-stranded
- 85 cDNA, ligated then isothermally amplified using a QIAseq FX single cell RNA library kit (Qiagen,
- 86 Hilden, Germany). Fragmentation and dual-index library preparation was conducted with an Illumina
- 87 DNA Prep, Tagmentation Library Preparation kit. Average library size was determined using a
- 88 Bioanalyser (Agilent Technologies; San Diego, CA, USA) and quantified with a Qubit 3.0
- 89 Fluorometer (Invitrogen; Carlsbad, CA, USA). Denatured libraries were sequenced on an Illumina
- 90 MiniSeq using a 300-cycle Mid-Output Reagent kit as per the manufacturer's protocol. Paired-end
- 91 Fastq reads were trimmed for quality and mapped to the published sequence for the SARS-CoV-2
- 92 reference isolate Wuhan-Hu-1 (RefSeq: NC\_045512.2) using CLC Genomics Workbench version 21
- 93 from which consensus sequences were generated. Stocks were confirmed to be free from
- ontamination by adventitious agents by analysis of reads that did not map to SARS-CoV-2 or cell-
- 95 derived sequences.

96

97

98

99

111

## **Human Plasma Samples**

Blood samples in EDTA blood collection tubes (BD Biosciences, Australia) were collected from healthy volunteers, aged between 25-70 (both female and male), who received COVID-19

vaccine manufactured by either AstraZeneca (Vaxzevria/AZD1222; University of Oxford-

- 100 AstraZeneca, Oxford/Cambridge, UK), Pfizer (Comirnaty/BNT162b2; BioNTech-Pfizer, Brooklyn,
- New York, USA), or Moderna (Spikevax/mRNA-1273; Moderna Inc, Cambridge, MA, USA) (**Table**
- 102 1). AstraZeneca vaccine was advised for the age group >60 [6]. Plasma was separated and stored at -
- 103 70°C until use. The study protocols were approved by institutional ethics committees of the Peter
- Doherty Institute, Melbourne Australia [University of Melbourne Central Human Research Ethics
- 105 Committee (2021-21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID
- 106 2021\_123\_RR). Biosafety protocols for handling the human samples and the infectious agents were
- approved by the Institutional Biosafety Committee of ACDP, Geelong before infectious work
- 108 commenced. Blood samples were collected on the day of vaccination (baseline; pre-1<sup>st</sup> dose) and 2
- weeks post second dose (2wk-2<sup>nd</sup> dose) for all the vaccine groups and after six months of 2<sup>nd</sup> dose
- 110 (6mo-2<sup>nd</sup> dose) and two weeks post third dose (2wk-3<sup>rd</sup> dose) for the Pfizer group.

### **Live-Virus Neutralisation Assays**

Virus neutralization assays (VNT) were carried out using Vero E6 cells as described previously

113 [5]. Briefly, each plasma sample for the three vaccines was diluted 1:10 in Dulbecco's Phosphate

Buffered Saline (DPBS; Thermo Fisher Scientific, Waltham, MA, USA) in a deep-well plate,

- followed by a two-fold serial dilution up to 1:1,280. The dilution series for each plasma sample was
- dispensed into triplicate columns of a 96-well plate (one plate per isolate), for a total volume of 50 µl
- per well. For the plasma-containing wells, 50 µl virus diluted in DMEM (Thermo Fisher Scientific,
- Waltham, MA, USA) containing 2% FBS, 2mM GlutaMAX supplement, 100U/mL penicillin, and
- 119 100 µg/mL streptomycin to contain approximately 100 TCID<sub>50</sub> (checked by back-titration) was added
- 119 100 µg/mL streptomycm to contain approximately 100 1Ch250 (checked by back-utration) was added
- 120 to each well. The plates were incubated at  $37^{\circ}\text{C}/5\%$  CO<sub>2</sub> for 1 h to allow neutralization complexes to
- form between the antibodies present in the plasma and the virus. A positive control serum was
- included to confirm the reproducibility of the assay. At the end of the incubation, 100 µl VeroE6
- cells were added to each well and the plates were returned to the incubator for 4 days. Each well was
- scored for the presence of viral CPE, readily discernible on Day 4 post-infection. NT<sub>50</sub> neutralization
- titres calculated using the Spearman–Karber formula [7], and transformed to log2 values for analysis.

Replicates that did not show neutralisation at 1:10 were scored <1:10 dilution and assigned a value 1:5 for statistical analysis in line with the current best practice [8].

### In silico Modelling

Molecular models were made of the trimeric Omicron Spike protein from residues 13 to 1160 (omitting the transmembrane domain) consistent with variant BA.1.1 and including glycosylation to visualize structural changes from the original strain. 'AlphaFold' [9] was used to reconstruct the N-terminal domain due to insertions and deletions. Models were built to include the 'up' and 'down' conformations of the Receptor Binding Domain (RBD, residues 330-530) as well as the human angiotensin converting enzyme 2 (ACE2) receptor. Building upon our previous work, [10] models were solvated and simulated using 'NAMDv2.14' software [11] for over 200 nanoseconds before visual assessment of changes to surface epitopes and receptor binding interfaces. More modelling details included in Supplementary Methods.

### **Statistical Analysis**

The VNT data were grouped based on vaccines, sex (female and male), and age groups (<35 – young; 35-60 – middle and >60 – senior). Both one-way and two-way Analysis of Variance (ANOVA) were used to test the statistical differences between vaccines, sex, age, day post vaccination/booster, variants, and their interactions. Levene's test for Homogeneity of Variance was performed before two-way ANOVA. If the ANOVA results returned a p-value of <0.05, a *post hoc* test with a Tukey's range test (Tukey's Honestly Significant Difference) was performed to measure the interactions between two variables. Plots were drawn using 'ggplot2' and all statistical procedures used the 'car' and 'lme' libraries in R [12]. Longitudinal data for continuous outcomes in multiple vaccine groups were compared using a linear mixed effects model. Subject identification number was added as a random variable while day post vaccination/booster (as a factor) and vaccine, sex and age groups and the interactions were considered as explanatory variables. In all models, explanatory variables were selected based on the lowest Akaike Information Criterion (AIC) using forward selection.

### **Results and Discussion**

### **Neutralisation of Delta and Omicron Variants of Concern**

**Table 1** shows the median ages for AstraZeneca sample donors are 57.5 compared to 38.5 for Moderna, and 33 for Pfizer vaccine donors respectively, the reasons for which are as follows. The Australian Technical Advisory Group on Immunisation (ATAGI) changed its recommendations regarding the AstraZeneca vaccine following reports of thrombotic thrombocytopenia syndrome (TTS) emerging from vaccinated adults [13]. It is worth noting that some individuals younger than 60 have received AstraZeneca vaccine following an assessment by a qualified health processional and with a verbal or written consent as provisioned by the Department Health, Government of Australia [6], but there is no brand preference for people aged 60 years and above because the benefits outweigh the risk of TTS in this age group. As a result, samples predominantly originated from young and middle-aged individuals for the Moderna and Pfizer vaccines, and from middle-aged and senior adults for the AstraZeneca vaccine. Given the large age range for the Pfizer vaccine, for this manuscript we classified the age groups in to young (<35 age), middle (35-60) and senior (>60). We chose 35 as the cut-off for middle age as it generally corresponds to parents of teen aged children and is used in metrics such as the Peterson-KFF health System Tracker [14] which has identified COVD-

19 as the second and third most important cause of death of people who are over and under 35, respectively. In Australia, Moderna vaccine was approved for use relatively recently (9 August 2021), while a third dose of the AstraZeneca is only approved in exceptional circumstances, therefore this study did not have access to third-dose samples for these vaccines.

168 169

170

171

172 173

174

175

176

177

178

179

180

181

182

183 184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

Calculation of fold changes using the data presented in **Table 2** and **Figure 1**, demonstrate that for the Pfizer vaccine there was an 8.2- and 5.5-fold reduction in NT<sub>50</sub> titres against VIC31 and Delta respectively 6 months after second dose administration (compared to two weeks), while the average titre against Omicron decreased from an estimated 1:6.3 (only 4/15 samples had quantifiable neutralization) to below assay detection limit for all samples at the same time points. Subsequently there was a 25.5- and 24.7-fold increase in titres against VIC31 and Delta respectively two weeks after a third dose administration (compared to 6 month post-second dose), while the average titre against Omicron increased from below assay detection limit to 1:48.5 at the same time points. Because of the aforementioned limitations, calculation of such fold changes for AstraZeneca and Moderna were not possible. However, it is worthwhile to compare their neutralisation titres two weeks post-second dose relative to the Pfizer vaccine samples. Across all three variants, we did not find any significant difference between Pfizer and Moderna vaccines by 2<sup>nd</sup> week post second dose of the vaccines (Supplementary Table S1).

ANOVA and Linear Mixed Models (*lm* and *lmer*) analyses were used to investigate the interactions of age, sex, vaccine, and day post vaccination/booster with neutralising antibody titres to the three different virus variants (Supplementary Text S1). One-way and two-way ANOVA analyses showed that, for all vaccines (Pfizer, Moderna and AstraZeneca), day post vaccination/booster and virus variant were the main contributors to differences in neutralising antibody responses, while age and sex did not have significant effects. Based on ANOVA analysis there was no significant difference in neutralising titres based on age or sex for any of the vaccines (Supplementary Tables S2 & S3; Figure 2A-C). However, based on Linear Mixed Models (lm) analysis, younger individuals tended to have higher neutralising antibody titres (Supplementary **Tables S4 & S5; Figure 3A-C).** The titres were dependent on the vaccine, day post-vaccination and variant (p<0.001) and to an extent the age where antibody titres in young showed statistically significant difference when compared to the middle and senior age groups (p=0.022). The antibody titres against Omicron have a negative slope and indicating that there is poor neutralisation with the variant.

In line with recent findings in similar studies by other groups [15,16], Omicron titres were significantly lower than VIC31-D614G and Delta titres at all time points and regardless of vaccine, highlighting the concern of poor protection to Omicron following vaccination by any of the three leading vaccines. One shortcoming of our data is the lack of later samples and post-boost (third vaccination) from individuals vaccinated with AstraZeneca and Moderna vaccines. However, the data available from Pfizer vaccinated individuals at 6 months after receiving their second dose indicate a significant waning of immunity to all three variants over this period. Neutralising antibody levels to Omicron were low or undetectable in most individuals two weeks after receiving two Pfizer doses, and below the assay limit of detection in all samples tested at 6 months after the second dose. However, at two weeks after the booster vaccination (third Pfizer dose), a significant booster effect in neutralising titres was noted to all three variants. This highlights the importance of the need for a booster (third) vaccine dose for ongoing protection against D614G and Delta variants, but more importantly that two doses are insufficient to stimulate significant neutralising protection against Omicron BA.1, therefore making the third dose essential. The cause of better protection against

specific mutations, is likely due to higher overall neutralising titres due to a booster effect despite neutralising antibodies to certain epitopes being circumvented.

Linear Mixed Model analysis of the variance between variables confirms the ANOVA analyses which showed that day post vaccination/booster and virus variant are the major contributors to titre differences, but further shows that there was a significant difference in neutralising titres elicited by the three different vaccines, mostly due to poor responses to the AstraZeneca vaccine. This analysis model further suggests that younger individuals (aged less than 35 years) are likely to have a stronger neutralising antibody response than older individuals, but we concede that this finding might be confounded by the distribution of the ages within the vaccine groups. This might also explain the poorer responses in the AstraZeneca group because of the vaccine advice in Australia (AstraZeneca mostly used in the older age group).

### In silico modelling and analysis

From structural perspectives, there are significantly more mutations in the Spike protein of the Omicron variant shown in **Figure 4A**, (37 mutations in the BA.1 variant, 32 in the BA.2 variant including insertions and deletions), compared to the Delta variant (10 mutations), while only one in the VIC31 strain (D614G). The Omicron mutations contribute to its ability to circumvent vaccine or infection induced neutralising antibody responses [**15,16**]. Three of these mutations (G142D, T478K and D614G) are common to Delta and Omicron, however we have previously shown experimentally and through *in silico* modelling that D614G has no significant impact on vaccines [**4**]. In the receptor binding domain (RBD) of the Spike protein alone, which is most immunologically exposed in its 'up' configuration and critical for ACE2 binding, there are 15 and 17 mutations in the Omicron BA.1 and BA.2 variants compared to only 2 in Delta as shown in **Figures 4A & C**. Many of the observed Omicron mutations by our analysis appear to be immune evasive, as they do not appear to be at the ACE2 binding interface and represent a significant change in the residue characteristics; in the RBD, these include N440K, K417N, S477N, T484K, and E484A.

Interestingly our isolate VIC28585 belongs to the BA.1.1 sub-lineage as it also contains the R346K spike mutation, which possibly further decreases antibody neutralization based on the reduced binding of class 2 antibodies in theoretical studies with the Mu variant of interest [17]. Nextgeneration sequencing results also indicated the presence of additional Spike mutations S373P and S375F in our VIC28585 isolate at frequency exceeding 99.8%; these two mutations with Grantham scores of 74 (moderately conservative change) and 155 (radical change) respectively are near the S371L Spike mutation characteristic to BA.1 which has a Grantham score of 145 (moderately radical change). Thus, we have investigated the neutralising responses to Omicron BA.1.1 in individuals vaccinated with three leading COVID-19 vaccines and compared these neutralising titres to those against an early SARS-CoV-2 isolate with the D614G mutation (VIC31), and the Delta variant (B.1.617.2) that subsequently became the dominant variant worldwide prior to Omicron's emergence. For example, on 11 December 2021 the ratio of Delta: BA.1: BA.1: BA.2: Other in USA (where extensive data is available from the CDC; [18]) was 92.5 : 5.2 : 2.2 : 0 : 0.2, and this steadily changed over two months so that on 12 February 2021 the ratio was 0: 22.9: 73.2: 3.9:0. This shows that BA.1.1, used in our study, could emerge as the dominant variant although we need to wait for more comprehensive data from around the world – as of 16 February 2022, 719,364 sequences of BA.1 were reported from 139 countries, while 410,015 sequences of BA.1.1 were reported from 127 countries.

Other Omicron mutations are likely to confer increased binding affinity to ACE2 by increasing molecular interactions such as salt bridges and pi-stacking [9]; these mutations include Q493R and O498R (increasing salt bridge interactions with ACE2's D38 and E35) and N501Y (also seen in Alpha, Beta and Gamma variants, pi-stacking with ACE2's Y41, shown in **Supplementary Figure** S1. A cluster of mutations S371L, S373P and S375F, interestingly appear co-located with Y505H in adjacent RBD domains in the 'down' position. These serine mutations, as well as significantly altering epitope presentation of the RBD domain by creating a more rigid structural motif, may allow H505 to interact with the adjacent F375, potentially modulating 'up'/'down' conformations via the ionizable H505, (pKa of 6.0). This structural change may coincide with the observed Omicron preference of infection to the bronchus, where pH is usually lower at 5.5 to 6.5, compared to the lung [19,20] (Supplementary Figure S2).

With the large number of mutations, it is unsurprising that the Omicron variant displays the observed antibody evasion and replicative advantage over earlier variants [21], as experimentally observed in our study. Our biomolecular modelling shows sufficient distinction between BA.1 and BA.2, therefore future studies should experimentally compare the two.

### **Public Health Implications and Future Studies**

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279 280

281 282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

The data we present here highlight the importance of booster vaccination for adequate protection against newly emerging variants such as Omicron BA.1. Further studies are needed to perform similar analyses of neutralising titres in individuals receiving "heterologous" booster doses, e.g., initial AstraZeneca vaccination followed by Moderna or Pfizer boost, or Pfizer-Moderna / Moderna-Pfizer.

In the early days of the pandemic, the scientific prediction was that SARS-CoV-2 will have a mutation rate similar to SARS-CoV (0.8-2.4x10<sup>-3</sup>) thanks to the 3'-to-5' exoribonuclease 'proofreading mechanism' in coronaviruses [22], which was thought to result in a reduction in the mutation rate ( $\sim 10^{-6}$  per site per cycle) compared to influenza ( $\sim 3 \times 10^{-5}$  per site per cycle) [23,24]. Therefore, it was predicted that vaccine matching may not be required as frequently as seasonal influenza (once a year each for Northern and Southern hemispheres), although this was hard to say definitively because SARS-CoV-2's genetic drift was uncertain with respect to the long-lasting efficacy of vaccine candidates then under development [25]. Early studies, for instance between 1 February to 1 May 2020 seemed to confirm the mutation rate prediction with a median estimate of  $1.12 \times 10^{-3}$  per site-year ([26]; we believe their upper 95% confidence interval should read  $1.85 \times 10^{-3}$ ).

Two years on, we have increasing evidence, including from this work, that the primary immunization schedule should consist of three rather than two doses, and indeed many countries are redefining 'fully vaccinated' status as three doses of these vaccines [27]. It is early to speculate on annual boosters beyond the third dose, although Israel has started to expand its fourth dose administration to groups beyond the immunocompromised [28,29]. These developments make it all the more important to ensure vaccine equity across the world so everyone is adequately protected, and highlight the potential need for vaccine matching to increase protection against infection. Vaccines using Spike as the primary antigen should consider including mutations common to BA.1, BA.1.1, and BA.2; development of vaccines with additional antigens, other than Spike, targeting more conserved viral factors should also be explored. This view is further supported by a recent preprint currently under peer review suggesting that, although a fourth dose restored anti-Omicron BA.1 neutralising antibody titres to a level observed post-third dose, breakthrough Omicron

In this context, it is important to explore vaccines that can better withstand mutations to the Spike protein better, and ideally have less dependence on cold chain. In addition to repeating this work with Omicron BA.2, it is also important to explore the benefits of T cell immunity and heterologous boosting (which are beyond the scope of this paper, but see for instance these studies [30-33]. Another aspect worth exploring is intranasal administration of selected vaccines. In the earliest study (conducted from March 2020) looking at intranasal administration of the AstraZeneca vaccine [34], we found that although neutralising antibody titres were 2-fold lower in ferrets receiving two doses of this vaccine intranasally compared to the intranuscular route, the former was more protected using virus shedding as an infection metric [35]. These findings were subsequently confirmed in hamsters and non-human primates [36], and also reportedly led to a small clinical trial in 30 humans [37]. We feel that the intranasal route, and the role of mucosal immunity, needs to be explored more comprehensively given that the AstraZeneca vaccine has the widest reach (183 countries worldwide), with over 2.5 billion doses administered [38].

### References

- 1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E et al. Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2020 [cited 20 February 2022]. Available from: https://ourworldindata.org/coronavirus
  - 2. World Bank. *World Bank Country and Lending Groups* (2022). Available at: <a href="https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups">https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</a>
  - 3. WHO. *Tracking SARS-CoV-2 variants* (2022). Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  - 4. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al. Experimental and in Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614g Mutation in Sars-Cov-2 Spike Protein. npj Vaccines (2020) 5(1):96. doi: 10.1038/s41541-020-00246-8.
  - 5. Malladi SK, Patel UR, Rajmani RS, Singh R, Pandey S, Kumar S, et al. Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric Sars-Cov-2 Receptor Binding Domain Derivative. ACS Infectious Diseases (2021) 7(8):2546-64. doi: 10.1021/acsinfecdis.1c00276.
  - 6. Australian Government Department of Health. *Vaxzevria* (*AstraZeneca*) (2022). Available at: <a href="https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/astrazeneca">https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/approved-vaccines/astrazeneca</a>
  - 7. Kärber G. Beitrag Zur Kollektiven Behandlung Pharmakologischer Reihenversuche. *Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie* (1931) 162(4):480-3. doi: 10.1007/BF01863914.
  - 8. Sitaras I, Personal Communication (16 Feb 2022) to S.S Vasan
  - 9. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly Accurate Protein Structure Prediction with AlphaFold. *Nature* (2021) 596(7873):583-9. doi: 10.1038/s41586-021-03819-2.
- 10. Kuiper MJ, Wilson LOW, Mangalaganesh S, Lee C, Reti D, Vasan SS. "But Mouse, You Are Not Alone": On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting Mice. *ILAR Journal* (2022). doi: 10.1093/ilar/ilab031.
- 11. Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, et al. Scalable
  Molecular Dynamics on Cpu and Gpu Architectures with Namd. *J Chem Phys* (2020)
  153(4):044130. doi: 10.1063/5.0014475.

12. R-Core-Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2019. Available online: <a href="https://www.r-project.org/">https://www.r-project.org/</a>

- 13. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after Chadox1 Ncov-19 Vaccination. *New England Journal of Medicine* (2021) 384(22):2092-101. doi: 10.1056/NEJMoa2104840.
  - 14. Peterson-KFF Health System Tracker. *COVID-19 leading cause of death ranking* (2022). Available at: https://www.healthsystemtracker.org/
    - 15. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma Neutralization of the Sars-Cov-2 Omicron Variant. *New England Journal of Medicine* (2021) 386(6):599-601. doi: 10.1056/NEJMc2119641.
    - 16. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. Sars-Cov-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. *New England Journal of Medicine* (2022) 386(7):698-700. doi: 10.1056/NEJMc2119236.
    - 17. Fratev F. R346k Mutation in the Mu Variant of Sars-Cov-2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study. *Journal of Chemical Information and Modeling* (2022) 62(3):627-31. doi: 10.1021/acs.jcim.1c01243.
    - 18. CDC. *COVID Data Tracker* (2022). Available at: <a href="https://covid.cdc.gov/covid-data-tracker-home">https://covid.cdc.gov/covid-data-tracker-home</a>
    - 19. Hui KPY, Ho JCW, Cheung M-c, Ng K-c, Ching RHH, Lai K-l, et al. Sars-Cov-2 Omicron Variant Replication in Human Bronchus and Lung Ex Vivo. *Nature* (2022). doi: 10.1038/s41586-022-04479-6.
  - 20. Fischer H, Widdicombe JH. Mechanisms of Acid and Base Secretion by the Airway Epithelium. *J Membr Biol* (2006) 211(3):139-50. Epub 20061107. doi: 10.1007/s00232-006-0861-0.
  - 21. Liu L, Iketani S, Guo Y, Chan JFW, Wang M, Liu L, et al. Striking Antibody Evasion Manifested by the Omicron Variant of Sars-Cov-2. *Nature* (2021). doi: 10.1038/s41586-021-04388-0.
  - 22. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, et al. Moderate Mutation Rate in the Sars Coronavirus Genome and Its Implications. *BMC Evol Biol* (2004) 4:21. Epub 20040628. doi: 10.1186/1471-2148-4-21.
  - 23. Bar-On YM, Flamholz A, Phillips R, Milo R. Sars-Cov-2 (Covid-19) by the Numbers. *eLife* (2020) 9:e57309. doi: 10.7554/eLife.57309.
  - 24. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R. Viral Mutation Rates. *J Virol* (2010) 84(19):9733-48. Epub 20100721. doi: 10.1128/jvi.00694-10.
  - 25. Bauer DC, Tay AP, Wilson LOW, Reti D, Hosking C, McAuley AJ, et al. Supporting Pandemic Response Using Genomics and Bioinformatics: A Case Study on the Emergent Sars-Cov-2 Outbreak. *Transbound Emerg Dis* (2020) 67(4):1453-62. doi: <a href="https://doi.org/10.1111/tbed.13588">https://doi.org/10.1111/tbed.13588</a>.
  - 26. Koyama T, Platt D, Parida L. Variant Analysis of SARS-CoV-2 Genomes. *Bull World Health* Organ (2020) 98(7):495-504. Epub 2020/06/02. doi: 10.2471/BLT.20.253591.
  - 27. Australian Government Department of Health. ATAGI statement on defining 'up-to-date' status for COVID-19 vaccination (2022). Available at: <a href="https://www.health.gov.au/news/atagi-statement-on-defining-up-to-date-status-for-covid-19-vaccination">https://www.health.gov.au/news/atagi-statement-on-defining-up-to-date-status-for-covid-19-vaccination</a>
  - 28. Burki TK. Fourth Dose of Covid-19 Vaccines in Israel. *The Lancet Respiratory Medicine* (2022) 10(2):e19. doi: 10.1016/S2213-2600(22)00010-8.
- 29. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. 4th Dose
  Covid Mrna Vaccines' Immunogenicity & Amp; Amp; Efficacy against Omicron Voc.
  medRxiv (2022):2022.02.15.22270948. doi: 10.1101/2022.02.15.22270948.

395 30. May DH, Rubin BER, Dalai SC, Patel K, Shafiani S, Elyanow R, et al. Immunosequencing and Epitope Mapping Reveal Substantial Preservation of the T Cell Immune Response to Omicron Generated by Sars-Cov-2 Vaccines. *medRxiv* (2021):2021.12.20.21267877. doi: 10.1101/2021.12.20.21267877.

- 31. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. Sars-Cov-2 Spike T Cell Responses Induced Upon Vaccination or Infection Remain Robust against Omicron. *medRxiv* (2021):2021.12.26.21268380. doi: 10.1101/2021.12.26.21268380.
- 32. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, et al. Homologous and Heterologous Covid-19 Booster Vaccinations. *New England Journal of Medicine* (2022). doi: 10.1056/NEJMoa2116414.
- 33. He Q, Mao Q, An C, Zhang J, Gao F, Bian L, et al. Heterologous Prime-Boost: Breaking the Protective Immune Response Bottleneck of Covid-19 Vaccine Candidates. *Emerg Microbes Infect* (2021) 10(1):629-37. doi: 10.1080/22221751.2021.1902245.
- 34. Jayaraman KS. Ferret Chosen as Animal Model to Test Coronavirus Vaccines. Nature India (5 April 2020). Available at: http://go.nature.com/39LGAqx.
- 35. Marsh GA, McAuley AJ, Au GG, Riddell S, Layton D, Singanallur NB, et al. Chadox1 Ncov-19 (Azd1222) Vaccine Candidate Significantly Reduces Sars-Cov-2 Shedding in Ferrets. *npj Vaccines* (2021) 6(1):67. doi: 10.1038/s41541-021-00315-6.
- 36. Van Doremalen N, Purushotham Jyothi N, Schulz Jonathan E, Holbrook Myndi G, Bushmaker T, Carmody A, et al. Intranasal Chadox1 Ncov-19/Azd1222 Vaccination Reduces Viral Shedding after Sars-Cov-2 D614g Challenge in Preclinical Models. *Science Translational Medicine* (2021) 13(607):eabh0755. doi: 10.1126/scitranslmed.abh0755.
- 37. Imperial College London. *Landmark coronavirus study to trial inhaled Imperial and Oxford vaccines* (2020). Available at: <a href="https://www.imperial.ac.uk/news/203653/landmark-coronavirus-study-trial-inhaled-imperial/">https://www.imperial.ac.uk/news/203653/landmark-coronavirus-study-trial-inhaled-imperial/</a>
- 38. BBC. *AstraZeneca vaccine: Did nationalism spoil UK's 'gift to the world'?* (2022). Available at: https://www.bbc.com/news/health-60259302
- 39. Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nature Methods* (2017) 14, 71-73, doi:10.1038/nmeth.4067
- 40. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* (2020) 367, 1260-1263 doi: 10.1126/science.abb2507
- 41. Watanabe Y, Allen, JD, Wrapp, J, McLellan, JS, Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike *Science* (2020) 369(6501):330-333. doi: 10.1126/science.abb9983.
- 42. Humphrey, W., Dalke, A. and Schulten, K., "VMD Visual Molecular Dynamics", J. Molec. Graphics, 1996, vol. 14, pp. 33-38.41

### Figures 1-4




Figure 1: Box Plots Showing 50% Neutralisation Titres (NT<sub>50</sub>) Against SARS-CoV-2 Variants of Concern with Plasma from Human Volunteers

Neutralisation of VIC31, Delta, and Omicron by human donor samples collected at different timepoints following vaccination with AstraZeneca (A), Moderna (B), or Pfizer (C) COVID-19 vaccines. The titres are shown in Log2 scale on the y-axis.




Figure 2: Box Plots Showing 50% Neutralization Titres (NT<sub>50</sub>) Against SARS-CoV-2 Variants of Concern Assessed by Sex of Donors

Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron (iii), with titres assessed with respect to sex. The titres are shown in Log2 scale in the y-axis. The ANOVA results of pairwise comparison between pre and post vaccinated sera for the different sexes are presented as adj p-values using Bonferroni post hoc test.




Figure 3: Box Plots Showing NT<sub>50</sub> Values Against SARS-CoV-2 Variants of Concern Assessed by Age Group

Plasma samples from human volunteers vaccinated with either AstraZeneca (A), Moderna (B), or Pfizer (C) vaccines were tested in neutralisation assays against VIC31 (i), Delta (ii), and Omicron (iii), with titres assessed with respect to age group. The titres are shown in Log2 scale in the y-axis. The ANOVA results of pairwise comparison between pre and post vaccinated sera for the different sexes are presented as adj p-values using Bonferroni post hoc test.




Figure 4: Structure of SARS-CoV-2 Spike Protein and Mutations of Interest

455

456

457

458 459 **A.** The Omicron spike protein with mutations shown in pink. A single S1 domain is highlighted in blue with the receptor binding domain (RBD) in the 'up' configuration is highlighted in cyan. Glycosylation is shown as green lines. **B.** & **C.** Comparison of the RBD in the Omicron and Delta variants, 15 mutations are observed in Omicron while only 2 in the Delta variant.

### **Tables 1 & 2**

460

461

462

463

464

465

466

467 468

### Table 1: Information on Human Participants, Vaccines, and Blood Collection Schedule

		AstraZeneca	Moderna	Pfizer
Donor		n=6	n=12	n=15
Sex	Male	n=3	n=6	n=5
Sex	Female	n=3	n=6	n=10*
Age	Male	58 (57-65)	41.5 (29-70)	31 (29-35)
[Median (Range)]	Female	57 (31-59)	38.5 (27-47)	33.5 (25-57)
	Overall	57.5 (31-65)	38.5(27-70)	33 (25-57)
	pre-1 <sup>st</sup> Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
Commiss Hand	2w Post-2 <sup>nd</sup> Dose	n=6 (3M, 3F)	n=12 (6M, 6F)	n=15 (5M, 10F)
Samples Used	6mo Post-2 <sup>nd</sup> Dose			n=15 (5M, 10F)
	2w Post-3 <sup>rd</sup> Dose			n=6 (3M, 3F)

<sup>\*</sup>For pre-1<sup>st</sup> dose and 2w post-2<sup>nd</sup> dose the samples are gender balanced.

# Table 2: Sex-Based Mean and Standard Deviation for VNT Titres Against SARS-CoV-2 Variants for Human Subjects Vaccinated with Different COVID-19 Vaccines.

Vassins	Corr	Estimates		VI	C31			De	lta			Omi	cron	
Vaccine Sex	Sex	Estimates	1	2	3	4	1	2	3	4	1	2	3	4
	E1-	Mean	2.32	3.46	X	X	2.32	2.32	X	X	2.32	2.32	X	X
	Female	SD	0.00	0.00	X	X	0.00	0.00	X	X	0.00	0.00	X	X
A atmo Zanaga	Molo	Mean	2.32	5.04	X	X	2.32	2.82	X	X	2.32	2.32	X	X
AstraZeneca	Male	SD	0.00	1.01	X	X	0.00	0.86	X	X	0.00	0.00	X	X
	All	Mean	2.32	4.25	X	X	2.32	2.57	X	X	2.32	2.32	X	X
	All	SD	0.00	1.08	X	X	0.00	0.61	X	X	0.00	0.00	X	X
	Female	Mean	2.32	7.16	X	X	2.32	5.99	X	X	2.32	2.57	X	X
	remale	SD	0.00	1.11	X	X	0.00	0.76	X	X	0.00	0.61	X	X
Moderna	Male	Mean	2.32	6.93	X	X	2.32	5.05	X	X	2.32	2.82	X	X
Moderna	Iviale	SD	0.00	1.17	X	X	0.00	1.28	X	X	0.00	0.80	X	X
	All	Mean	2.32	7.04	X	X	2.32	5.52	X	X	2.32	2.69	X	X
	All	SD	0.00	1.09	X	X	0.00	1.12	X	X	0.00	0.69	X	X
	Female	Mean	2.32	7.22	3.75	7.93	2.32	6.36	3.37	7.39	2.32	2.73	2.32	4.59
	Telliale	SD	0.00	1.08	0.66	0.38	0.00	1.04	0.79	0.51	0.00	0.67	0.00	0.71
DC: M	Male	Mean	2.32	6.76	4.61	9.49	2.32	5.76	4.34	9.27	2.32	2.49	2.32	6.63
Pfizer	iviale	SD	0.00	0.92	0.71	0.67	0.00	1.06	0.97	0.77	0.00	0.38	0.00	1.17
	All	Mean	2.32	7.07	4.04	8.71	2.32	6.15	3.70	8.32	2.32	2.65	2.32	5.60
	All	SD	0.00	1.02	0.78	0.98	0.00	1.05	0.95	1.19	0.00	0.59	0.00	1.40

All VNT titres expressed as Log2 values. Values indicated as 2.32 represent titres below the assay detection limit.  $SD = Standard Deviation of Mean; 1 = -1^{st} dose; 2 = 2wk-2^{nd} dose; 3 = 6mo-2^{nd} dose and 4 = 2wk-3^{rd} dose. X = sample not available for analysis$ 

## Data Availability Statement

- The original contributions presented in the study are included in the article/Supplementary Material.
- 471 Further inquiries can be directed to the corresponding author.

### 472 Ethics Statement

469

- The study protocols were approved by institutional ethics committees of the Peter Doherty Institute,
- 474 Melbourne Australia [University of Melbourne Central Human Research Ethics Committee (2021-
- 475 21198-15398-3)] and the CSIRO (CSIRO Human Research Ethics Committee ID 2021 123 RR).
- The reference serum for the neutralisation assay was derived from an animal study reviewed and
- approved by CSIRO ACDP Animal Ethics Committee (AEC 2004).

### 478 **Author Contributions**

- NBS designed the study with PJvV, AJM, SMG and SSV. PJvV and AJM performed the experiments
- with MPB, SR and SG. NBS and SMG analysed the experimental data and provided statistical
- interpretations, with inputs from PJvV, AJM, TWD and SSV. MJK performed biomolecular
- 482 modelling and provided structural interpretations. LC and JDD isolated the virus variants, which
- 483 were sequenced by KRB and MT. JAJ, SJK and AKW provided the human plasma samples and
- obtained the necessary funding for the same. SM, SC and SSV analysed the health economic
- implications. NBS, PJvV, AJM, MJK, SM, SC and SSV co-wrote the manuscript, and all authors
- 486 contributed to revisions and creation of the final version. SV conceived the conceived the project and
- 487 obtained funding.

### Funding

488

498

503

- This work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO's Precision
- 490 Health & Responsible Innovation Future Science Platforms, National Health and Medical Research
- 491 Council (grant MRF2009092), and United States Food and Drug Administration (FDA) Medical
- 492 Countermeasures Initiative (contract 75F40121C00144). J.A.J., S.J.K. and A.K.W. are grateful to the
- National Health and Medical Research Council (for grants GNT2002073, MRF2005544,
- 494 GNT1149990, fellowships and an investigator grant). We also thank the Victorian Government,
- 495 especially the Victorian Department of Health and Human Services, the major funder of the Victorian
- 496 Infectious Diseases Reference Laboratory and Barwon Health. The article reflects the views of the
- authors and does not represent the views or policies of the funding agencies including the FDA.

### **Conflict of Interest**

- 499 All claims expressed in this article are solely those of the authors and do not necessarily represent
- those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any
- product that may be evaluated in this article, or claim that may be made by its manufacturer, is not
- guaranteed or endorsed by the publisher.

### Acknowledgments

- 504 The authors are grateful for support from Professor Sharon Lewin, Professor Deborah Williamson
- and colleagues at the Peter Doherty Institute for Infection and Immunity
- 506 (https://www.grid.ac/institutes/grid.483778.7) and the CSIRO's Australian Centre for Disease
- 507 Preparedness (ACDP; https://www.grid.ac/institutes/grid.413322.5), especially Dr Daniel Layton and

- 508 Kristen McAuley. We thank Dr Amy Shurtleff of the Coalition for Epidemic Preparedness
- 509 Innovations and the University of Oxford's Professors Teresa Lambe and Dame Sarah Gilbert for
- access to positive control ferret sera from their study (CSIRO ACDP Animal Ethics Committee
- 511 Approval Reference: AEC 2004).

## **Supplementary Material**

512

513

515

516517

518

521

522

## Supplementary Tables S1 to S5

## 514 Supplementary Table S1: Comparison for NT50 values on 2<sup>nd</sup>-2wk

Comparison	Variant	Estimate ('adjusted' p-value)
Pfizer vs Moderna	VIC31	p=1.00
Pfizer vs Moderna	Omicron	p=1.00
Pfizer vs Moderna	Delta	p=0.48

# Supplementary Table S2: One-way ANOVA results for vaccines, variants, sex, age and day post vaccination/boosters

Vaccine	Variable	F-value	p-value	Significance
Pfizer	Sex	2.421	0.122	NS
	Age	0.859	0.355	NS
	Day post vaccination/booster	73.84	<2e-16	***
	Variant	16.61	3.05E-07	***
Moderna	Sex	0.104	0.748	NS
	Age	0.074	0.929	NS
	Day post vaccination/booster	64.56	1.58E-11	***
	Variant	8.839	0.000382	***
AstraZeneca	Sex	1.497	0.230	NS
	Age	1.401	0.261	NS
	Day post vaccination/booster	7.722	0.00882	**
	Variant	5.744	0.00724	**

# Supplementary Table S3: Two-way ANOVA results of interactions for vaccines, variants, sex, age and day post vaccination/boosters

Vaccine	Factor	Factor	F-value	p-value	Significance
Pfizer	Variant	Sex	0.047	0.954	NS
		Age	0.018	0.983	NS
		Day post vaccination/booster	26.31	<2E-16	***
Moderna	Variant	Sex	0.158	0.583	NS
		Age	0.052	0.995	NS
		Day post vaccination/booster	59.91	1.46E-15	***
AstraZeneca	Variant	Sex	0.872	0.429	NS
		Age	0.507	0.731	NS
		Day post vaccination/booster	13.00	8.70E-05	***

## 523 Supplementary Table S4: Linear Mixed Models (lm) for analysis of variance between variables

Model	df	AIC	Forward selection
Titre~1	2	1124.513	No
Titre~Sex	3	1125.835	No
Titre~Age	4	1123.255	No
Titre~Day	5	939.998	Yes
Titre~Vaccine	4	113.991	No
Titre~Variant	4	1081.153	No
Titre~Day+Sex	5	941.652	No
Titre~Day+Age	6	934.913	No
Titre~Day+Vaccine	7	926.686	No
Titre~Day+Variant	7	833.830	Yes
Titre~Day+Variant+Sex	8	835.303	No
Titre~Day+Variant+Age	9	823.844	No
Titre~Day+Variant+Vaccine	9	810.945	Yes
Titre~Day+Variant+Vaccine+Sex	10	811.523	No
Titre~Day+Variant+Vaccine+Age	11	809.378	Yes

524

526

527

## 525 Supplementary Table S5: Summary statistics for model lm(Titre~Day+Variant+Vaccine+Age)

Estimate	Std. Error	t-value	Pr(> t )	Signif.
1.626	0.2327	6.989	2.49E-11	***
2.4878	0.1585	15.696	<2.00E-16	***
0.7876	0.2185	3.605	0.000376	***
5.0109	0.2988	16.769	<2.00E-16	***
-1.4357	0.1691	-8.491	1.82E-15	***
0.5685	0.1691	3.362	0.000894	***
0.8981	0.2336	3.844	0.000153	***
0.9608	0.2379	4.039	7.14E-05	***
0.2599	0.2972	0.875	0.38268	
0.363	0.1575	2.305	0.021988	*
	1.626 2.4878 0.7876 5.0109 -1.4357 0.5685 0.8981 0.9608 0.2599	1.626  0.2327    2.4878  0.1585    0.7876  0.2185    5.0109  0.2988    -1.4357  0.1691    0.5685  0.1691    0.8981  0.2336    0.9608  0.2379    0.2599  0.2972	1.626  0.2327  6.989    2.4878  0.1585  15.696    0.7876  0.2185  3.605    5.0109  0.2988  16.769    -1.4357  0.1691  -8.491    0.5685  0.1691  3.362    0.8981  0.2336  3.844    0.9608  0.2379  4.039    0.2599  0.2972  0.875	1.626      0.2327      6.989      2.49E-11        2.4878      0.1585      15.696      <2.00E-16

## Supplementary Text S1: Summary statistics for model

### lmer(Titre~Day+Variant+Vaccine+Age+(1|subject))

Linear mixed model fit by REML ['lmerMod']

Formula: titre  $\sim$  variant + day + vaccine + (1 | subject)

532 REML criterion at convergence: 807.3

533 Scaled residuals:

528529

534 535

539 540

541 542

Min	1Q	Median	3Q	Max
-2.3131	-0.8867	-0.0175	0.8057	3.4851

Random effects:

Groups	Name	Variance	Std.Dev.
subject	(Intercept)	0.000	0.000
Residual		1.260	1.123

Number of obs: 261, groups: subject, 33

538 Fixed effects:

	Estimate	Std. Error	t-value
(Intercept)	1.7299	0.2259	7.658
Omicron	-1.4357	0.1702	-8.434
VIC31	0.5685	0.1702	3.34
2wk-2 <sup>nd</sup> dose	2.4878	0.1596	15.591
6mo-2 <sup>nd</sup> dose	0.7876	0.2199	3.581
2wk-3 <sup>rd</sup> dose	4.9867	0.3006	16.587
Moderna	1.0191	0.2292	4.447
Pfizer	1.1232	0.2214	5.074

Correlation of Fixed Effects:

Correlation of I	med Emec						
	(Intr)	Omicron	VIC31	2wk-2 <sup>nd</sup> dose	6mo-2 <sup>nd</sup> dose	2wk-3 <sup>rd</sup> dose	Moderna
Omicron	-0.377						
VIC31	-0.377	0.500					
2wk-2 <sup>nd</sup> dose	-0.353	0.000	0.000				
6mo-2 <sup>nd</sup> dose	-0.128	0.000	0.000	0.363			
2wk-3 <sup>rd</sup> dose	-0.094	0.000	0.000	0.265	0.308		
Moderna	-0.676	0.000	0.000	0.000	0.000	0.000	
Pfizer	-0.700	0.000	0.000	0.000	-0.288	-0.210	0.690


## **Supplementary Methods**

### in silico Modelling


Molecular simulations were performed using NAMD2.14 with CHARM36m forcefield [39] employing a TIP3 water model. The Spike model was based on the pdb structure 6VSB3 [40], built with additions segments predicted with AlphaFold. The Spike protein only included residues 13 to 1160 (omitting transmembrane domain, to reduce the simulation size). Glycosylation of the Spike protein was manually constructed using Visual Molecular Dynamics (VMD) guided by glycan analysis [41]. Omicron models were constructed in two conformations, all RBD 'down', and 2 RBD 'down' one RBD 'up'. Both models included an ACE2 domain in the expected binding position.

Simulations were run with Periodic Boundary Conditions 'PBCs' using the NPT ensemble at 310K and 1 bar pressure employing Langevin dynamics. The PBCs were constant in the XY dimensions. Long-range Coulomb forces were computed with the Particle Mesh Ewald method with a grid spacing of 1 Å. 2 fs timesteps were used with non-bonded interactions calculated every 2 fs and full electrostatics every 4 fs while hydrogens were constrained with the 'SHAKE' algorithm. The cut-off distance was 12 Å with a switching distance of 10 Å and a pair-list distance of 14 Å. Pressure was controlled to 1 atmosphere using the NoséHoover Langevin piston method employing a piston period of 100 fs and a piston decay of 50 fs. Trajectory frames were captured every 100 ps. Simulations were performed for at least 200 nanoseconds. Trajectories were visualized and analysed using VMD [42].

### **Supplementary Figures**



**Supplementary Figure S1.** a) Omicron spike protein binding to ACE2 domain (shown in yellow). S1 domain shown in blues, with the receptor binding domain shown in cyan. Glycosylation is shown as green sticks. b) close up of the ACE2 binding interface of Omicron spike RBD showing the interaction of contacting residues.



**Supplementary Figure S2.** Close up of Omicron mutations in adjacent receptor binding domains (pink and blue) in 'down' position showing the close proximity of residues L371, P373 and F375 on the blue domain to the adjacent H505. This complementary arrangement may have influence on the RBD 'up'/'down' transitions by pH dependant ionization of H505.